louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06534801: Sequential Method Determination of Oxycodone for Thoracoscope Surgery Median Effective Dose of Acute Pain Treatment
Official title: Sequential Method Determination of Oxycodone for Thoracoscope Surgery Median Effective Dose of Acute Pain Treatment
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Oxycodone
Thoracoscopic Lobectomy
Acute Postoperative Pain
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2024-08-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to measure the median effective dose of oxycodone for the treatment of acute pain after thoracoscopic lobectomy. This clinical trial was divided into two groups based on age, Group I (Age \< 65 years old) and Group II (Age ≥65 years old). We used the sequential allocation designed by Dixon. The initial oxycodone dose was set to 0.1 mg/kg.A satisfactory or an unsatisfactory analgesic response of the previous patient determined, respectively, the relative 10% decrease or increase in the dose of oxycodone the next patient received in the same group. The patient before the first crossover point was included as the first case for ED50 estimation in each group.The study was conducted until 7 crossover points were collected


Eligibility criteria: Inclusion Criteria:

1. The first unilateral thoracoscopic lobectomy was performed under general anesthesia
2. age 18- 80 years old
3. American Society of Anesthesiologists (ASA) physical status I-III
4. Sign the informed consent of the patients

Exclusion Criteria:

1. Moderate to severe obesity (i.e., BMI \> 30kg/m2)
2. Allergic or hypersensitive reaction to oxycodon
3. A history of chronic pain
4. Patients with significant heart, pulmonary, liver or renal disease

Primary outcomes:
measure: The median effective dose
timeFrame: 3 minutes after remoal of the endotracheal tube, 30minutes after remoal of the endotracheal tube
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00973401: Retinal Function in Relation to Long Term Changes in the Glucose Level
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes Mellitus
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
First posted: 2009-09-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 type 1 diabetics without diabetic retinopathy, with dysregulated metabolic status that is to be medically optimized.

Brief summary: The purpose of this study is to measure the amplitude and implicit time of electroretinogram (ERG), darkadaptation and the calibre of retinal vessels before and after optimized medical treatment of diabetic individuals (a lower blood glucose level) over a period of 12 months. Newly diagnosed type 1 and type 2 diabetics as well as dysregulated type 1 and type 2 diabetic individuals will be included. Retinal vessel calibre measurements will be used as an estimation of changes in the retinal perfusion.


Eligibility criteria: Inclusion Criteria:

* Dysregulated type 1 diabetic individuals and newly diagnosed type 1 diabetics. Age \>17 \< 60 years

Exclusion Criteria:

* Test individuals with significant cataract, prior surgery to the eye, diabetic retinopathy, other serious eye disease, hypertension, other serious systemic disease.

Primary outcomes:
measure: Changes in amplitude/implicit times, retinal vessel diameter, dark adaptation and OCT
timeFrame: 1 week, 1 month, 4 months, 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Glostrup Hospital
Study officials:
References:
Clinical trial NCT03868501: High Working Memory Load to Reduce Internet Gaming Disorder (IGD) Cravings
Official title: High Working Memory Load to Reduce IGD Cravings: N-Back Task
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Internet Gaming Disorder
Lead sponsor: Beijing Normal University
Sponsor class: OTHER
First posted: 2019-03-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: To test whether high working memory load can effectively reduce the craving for IGD.

Detailed description: This project is to use 1-back task and 3-back task to reduce the craving of internet gamers. To test whether high working memory load can effectively reduce the craving for IGD. This project will be conducted in Beijing, China, based on a large sample of internet gamers.

Eligibility criteria: Inclusion Criteria:

* The scores of the 9 items of The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5) recommended diagnosis for Internet gaming disorder ≥ 5.
* Engagement in popular Internet games (e.g. Arena of Valor, League of Legends and Player Unknown's Battle Grounds) for over 20 hours per week for a minimum of 12 months.
* The scores of theYoung-Internet Addiction Test(Y-IAT) ≥ 50

Exclusion Criteria:

* Current or history of use of illegal substances and gambling;
* Current or history of psychiatric or neurological illness;
* Current use of psychotropic medications.

Primary outcomes:
measure: The craving of internet gamers
timeFrame: 0-1 minutes before each set of cue
measure: The craving of internet gamers after cue
timeFrame: 0-1 minutes after showing cue
measure: The craving of internet gamers after tasks
timeFrame: 0-1 minutes after finishing each block of tasks
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University
state: Beijing
Study officials:
affiliation: Study Principal Investigator
name: Jin-Tao Zhang, PhD
role: STUDY_DIRECTOR
References:
citation: Kaag AM, Goudriaan AE, De Vries TJ, Pattij T, Wiers RW. A high working memory load prior to memory retrieval reduces craving in non-treatment seeking problem drinkers. Psychopharmacology (Berl). 2018 Mar;235(3):695-708. doi: 10.1007/s00213-017-4785-4. Epub 2017 Nov 27.
citation: May J, Andrade J, Panabokke N, Kavanagh D. Visuospatial tasks suppress craving for cigarettes. Behav Res Ther. 2010 Jun;48(6):476-85. doi: 10.1016/j.brat.2010.02.001. Epub 2010 Feb 7.
Clinical trial NCT05578001: Efficacy of Pilocarpine 1% in Presbyopia
Official title: Efficacy of Pilocarpine 1% in Pseudophakia Individuals With Presbyopia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Presbyopia
Pseudophakia
Keywords: Pilocarpine
Presbyopia
Pseudophakia
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2022-10-13
Enrollment: 25
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: In this before-after interventional study on patients with presbyopia after cataract surgery, uncorrected distance vision and corrected distance visual acuity are measured and recorded by Snellen chart. Corrected near visual acuity from a distance of 40 cm is measured by the standard near vision chart (Rosenbaum near vision card). Twenty minutes after the administration of pilocarpine 1%, the corrected near and far visual acuity is measured again. Also, the relationship between the difference in average near visual acuity after the administration of 1% pilocarpine in pseudophakic people is measured with iris color and pupil size.

Detailed description: After selecting the study cases, the pupil size in both photopic and scotopic conditions and iris color(based on Simionescu's classification) will be recorded. Uncorrected distance visual acuity(UCDVA) will be measured by Snellen chart. Then the appropriate glasses will be placed according to the person's refraction and the corrected distance visual acuity(BCDVA) will be measured. Without changing the fitted glasses, corrected near visual acuity(BCNVA) is measured from a distance of 40 cm by the standard near vision chart (Rosenbaum near vision card). After this stage, one drop of pilocarpine 1% is prescribed in the patient's eye and 20 minutes later, the corrected near and far visual acuity is measured again. Thirty minutes and 8 hours after the administration of pilocarpine drop, the side effects of the drug, including headache, eye pain, eye redness, eye irritation, tearing, and blurred vision at night, are checked.

Eligibility criteria: Inclusion Criteria:

* Informed consent to participate in the study
* Previous uncomplicated cartaract surgery and PCIOL insertion
* BCDVA eqaul to or more than 8/10
* Less than 1.5 diopter cylindrical refractive error
* Spherical refractive error between -0.5_+1.5
* No history of previous eye disease
* Not using drugs that interact with pilocarpine

Exclusion Criteria:

* Occurrence of any drug-related complications
* Unable to follow up the patient after prescribing the drug

Primary outcomes:
measure: Best Corrected Near Visual Acuity
timeFrame: 20 minutes
Secondary outcomes:
measure: Best Corrected Distance Visual Acuity
timeFrame: 20 minutes
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Isfahan Eye Research Center
Study officials:
affiliation: Isfahan University of Medical Sciences, Isfahan, Iran
name: Alireza Peyman, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT00938301: A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
Official title: A Phase 1, Placebo-Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bipolar Depression
Keywords: healthy volunteer, first in human, safety and tolerability
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-07-13
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this first in human (FIH) study is to investigate the safety, tolerability, pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects the body) of PF-04455242-01 in healthy adult volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female of non-childbearing potential between the ages of 18 and 55 years.
* Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight \>50 kg (\>110 lbs).
* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

* Evidence or history of clinically significant medical condition or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening).
* Use of tobacco- or nicotine-containing products within 3 months of screening or a positive urine or blood cotinine at screening.
* A positive urine drug screen. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men.

Primary outcomes:
measure: Safety and tolerability of single doses will include neurological assessment, vital signs and adverse event reporting during inpatient stay.
timeFrame: Daily
measure: Physical exam
timeFrame: Screening, End of Trial (EOT), and Follow Up (F/U)
measure: Clinical safety laboratory results
timeFrame: Screening, Day 0 (D0), D2, F/U
measure: 12-lead ECGs
timeFrame: Screening, D1, D2, F/U
measure: Maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), area under the concentration-time curve (AUC) and terminal half-life (t1/2) .
timeFrame: 0 hr (predose) then 0.5-1 hr for the next 12 hrs postdose on D1, then 24, 36, 48, & 72 hrs postdose
Secondary outcomes:
measure: Likert and Drug Effect Questionnaire (DEQ) questionnaires
timeFrame: 0 hr (predose) then 1, 2, 3, 4, 6 ,8, & 12 hrs (postdose) on D1, then 24 hrs (postdose) on D2
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00284401: Prosthetic Component Relationship of the Reversed Delta III Total Shoulder Prosthesis in the Transverse Plane of the Body
Official title: Prosthetic Component Relationship of the Reversed Delta III Total Shoulder Prosthesis in the Transverse Plane of the Body
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Prosthesis
Keywords: Reversed prosthesis
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2006-01-31
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Comparison of the function and mobility of the shoulder with the placement of the Delta prosthesis (anteversion and retroversion of the glenoidal and humeral components)


Eligibility criteria: Inclusion Criteria:

* Shoulder prosthesis

Exclusion Criteria:

* Inability to place the hand on the back in prone position

Primary outcomes:
measure: Function and mobility of the shoulder
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Rene Verdonk, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03387501: Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium
Official title: Efficacy and Safety of the Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium in Patients Undergoing Transfer of Cryo-preserved Embryos: Clinical Trial II.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Infertility
Infertility, Female
Lead sponsor: Hospital San Carlos, Madrid
Sponsor class: OTHER
First posted: 2018-01-02
Enrollment: 13
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)


Eligibility criteria: Inclusion Criteria:

* Women who signed informed consent.
* Women who understand the Spanish language.
* Women under 42 years

Exclusion Criteria:

* Thrombopenia.
* Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
* Ovarian tumors.
* Benign uterine tumors require surgical treatment
* Local acute inflammatory diseases
* Patients with malignant tumors requiring chemotherapy.
* Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
* Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)

Primary outcomes:
measure: Percentage of women who achieve an endometrial thickness equal to or greater than 7 mm
timeFrame: 3 days after administration of PRGF
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
Study officials:
affiliation: Hospital Clinico San Carlos
name: Sara Rafael, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01316601: A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Crohn's Disease
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2011-03-16
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas

* Trial with medicinal product


Eligibility criteria: Inclusion criteria: - diagnosis of Crohn's disease \> 6 month with fistula - at least 1 ineffective fistula treatment in the past

Exclusion criteria: - TNF a antibody treatment failed in the past

- planned surgery

Primary outcomes:
measure: complete closure of fistula
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
Clinical trial NCT04106167: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Official title: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Advanced Solid Tumor
Lymphoma
Gastric Cancer
Colorectal Cancer
Head and Neck Cancer
Squamous Cell Carcinoma
EGFR Positive Solid Tumor
HER2-positive Breast Cancer
Hepatocellular Carcinoma
Small-cell Lung Cancer
Renal Cell Carcinoma
Pancreas Cancer
Melanoma
NSCLC
Urothelial Carcinoma
Cervical Cancer
Microsatellite Instability
Merkel Cell Carcinoma
Lead sponsor: Fate Therapeutics
Sponsor class: INDUSTRY
First posted: 2019-09-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with advance solid tumors rolling over from interventional study where they were treated with an allogeneic, iPSC-derived NK cell.

Brief summary: Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

Detailed description: This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Eligibility criteria: Inclusion Criteria:

* Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
* Subjects who have provided Informed consent prior to their study participation

Exclusion Criteria:

* Not Applicable

Primary outcomes:
measure: Overall Survival (OS) post-Infusion
timeFrame: From the date of study entry until the date of documented death due to any cause, assessed up to 60 months.
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: UCSD Moores Cancer Center
state: California
city: Minneapolis
country: United States
facility: University of Minnesota Masonic Cancer Center
state: Minnesota
city: Hackensack
country: United States
facility: Hackensack University Medical Center
state: New Jersey
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: Fate Therapeutics
name: Fate Trial Disclosure
role: STUDY_DIRECTOR
References:
Clinical trial NCT04943367: Effect of TEAS on Rocuronium Injection Pain
Official title: Efficacy of TEAS On Prevention of Rocuronium Injection Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Injection Pain
Lead sponsor: Konya Meram State Hospital
Sponsor class: OTHER
First posted: 2021-06-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pain from the injection of rocuronium is a common side effect during anesthetic practice, occurring in 50%-80% of patients. Several methods have been used to reduce this pain. This prospective, randomized study was designed to determine the efficacy of transcutaneous electrical acupuncture point stimulation in reducing the rocuronium injection pain.


Eligibility criteria: Inclusion Criteria:

* 18-65 year aged
* ASA I-III
* Who was to undergo various elective operations.

Exclusion Criteria:

* Cardiovascular surgery
* Patients with pacemakers
* Patients requiring rapid sequential induction

Primary outcomes:
measure: Pain with rocuronium injection
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: Betul Kozanhan
Study officials:
References:
Clinical trial NCT04047667: Cone Beam CT Guided Transbronchial Cryobiopsy
Official title: The Safety and Diagnostic Efficacy of Cone Beam CT Guided Transbronchial Cryobiopsy for ILD Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ILD
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2019-08-07
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ILD Patients without a diagnosis after integration of clinical profile, laboratory tests and HRCT features

Brief summary: Interstitial lung diseases (ILD) are common in clinical practices and need multidisciplinary assessment of clinical presentations, radiological and histological features. Transbronchial cryobiopsy (TBCB) is one of the most important invasive procedures for ILD when a confident diagnosis cannot be made by clinical and radiological assessment. TBCB could lead to higher incidence of risks. The pneumothorax and severe bleeding seemed to be more common in patients with TBCB.

Cone-beam computed tomography (CBCT) could provide 3-dimensinal (3D) CT images which were close to the image qualities of conventional CT. The probe-to-pleura relationship could be accurately established by the 3D CT scan and the cryobiopsy safety profile might be improved under the guidance of CBCT. In this study, we conducted a prospective study to observe the safety and diagnostic efficacy of CBCT guided TBCB for the DPLD patients.


Eligibility criteria: Inclusion Criteria:

* more than 18 years old, diffuse parenchymal lung diseases without a diagnosis after integration of clinical profile, laboratory tests and HRCT features, FVC more than 50%, DLCO more than 35%

Exclusion Criteria:

* acute exacerbation within one month, bleeding diathesis, anticoagulant therapy, using antiplatelet drugs, patients with pulmonary hypertension, respiratory failure, liver, kidney disfunction, and cardiac insufficiency, PLT less than 50 x 109/L

Primary outcomes:
measure: safety profile of procedure
timeFrame: 30 days
Secondary outcomes:
measure: diagnostic efficacy
timeFrame: 30 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: China-Japan Friendship Hospital
state: Beijing
Study officials:
References: